GHP Q2 2019

4 GHP / Q2 2019 NEWS , FDA Approves First Chemoimmunotherapy Regimen For Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma The U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non- Hodgkin lymphoma.